Cigna to Cover NanoString's Prosigna® Breast Cancer Assay
News May 27, 2016
Cigna and its roughly 13 million members join other payors now covering Prosigna, collectively representing more than 135 million covered lives throughout the United States.
This positive coverage decision is in line with updated ASCO guidelines released in February, wherein Prosigna is considered medically necessary to assess the necessity of adjuvant chemotherapy in ER-positive, HER2-negative, node-negative breast cancer patients, when adjuvant chemotherapy is not precluded due to any other factor.
"Cigna's decision to cover Prosigna is another milestone in expanding access to this state-of-the-art-test," said Brad Gray, president and chief executive officer of NanoString Technologies. "We estimate that more than 80% of patients indicated for Prosigna testing are now covered and our team is dedicated to working with the remaining health insurance providers to ensure that their patients have access to this important test."
A simple blood test reliably detects signs of brain damage in people on the path to developing Alzheimer’s disease – even before they show signs of confusion and memory loss, according to a new study from Washington University School of Medicine in St. Louis and the German Center for Neurodegenerative Diseases in Germany.READ MORE
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019